These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. Kordon A; Kahl KG; Broocks A; Voderholzer U; Rasche-Räuchle H; Hohagen F Eur Arch Psychiatry Clin Neurosci; 2005 Feb; 255(1):48-50. PubMed ID: 15538591 [TBL] [Abstract][Full Text] [Related]
12. Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. Wagner KD; Cook EH; Chung H; Messig M J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S53-60. PubMed ID: 12880500 [TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up study of patients with serotonin reuptake inhibitor-nonresponsive obsessive-compulsive disorder. Reddy YC; Alur AM; Manjunath S; Kandavel T; Math SB J Clin Psychopharmacol; 2010 Jun; 30(3):267-72. PubMed ID: 20473061 [TBL] [Abstract][Full Text] [Related]
14. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report. Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661 [TBL] [Abstract][Full Text] [Related]
15. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523 [TBL] [Abstract][Full Text] [Related]
16. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. Simpson HB; Gorfinkle KS; Liebowitz MR J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976 [TBL] [Abstract][Full Text] [Related]
17. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953 [TBL] [Abstract][Full Text] [Related]
18. The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder. Shavitt RG; Valério C; Fossaluza V; da Silva EM; Cordeiro Q; Diniz JB; Belotto-Silva C; Cordioli AV; Mari J; Miguel EC Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):91-9. PubMed ID: 20077119 [TBL] [Abstract][Full Text] [Related]
19. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922 [TBL] [Abstract][Full Text] [Related]